By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
AVEO Oncology (AVEO) Forges $326 Million Antibody Pact With Novartis AG (NVS) 8/17/2015 5:36:47 AM
AVEO Oncology (AVEO) Reports Second Quarter 2015 Financial Results 8/10/2015 10:00:43 AM
AVEO Oncology (AVEO) To Host Midyear Update Conference Call On August 10, 2015 8/5/2015 11:49:37 AM
AVEO Oncology (AVEO) Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS 8/5/2015 11:01:19 AM
AVEO Oncology (AVEO) Announces Additional Biomarker Analyses From BATON-CRC Tivozanib Study To Be Presented At The ESMO 17th World Congress On Gastrointestinal Cancer 6/30/2015 11:24:05 AM
AVEO Oncology (AVEO) Tumbles on Disappointing FDA Feedback for Tivozanib 6/12/2015 5:57:38 AM
Nearly-Dead AVEO Oncology (AVEO)'s Stock Jumps on Positive European Regulatory Promises 6/4/2015 7:00:31 AM
AVEO Oncology (AVEO) To Present At Jefferies and Co. 2015 Global Healthcare Conference 5/29/2015 11:30:58 AM
AVEO Oncology (AVEO) Relocates HQ to Smaller Facility in Cambridge After Corporate Restructuring 5/26/2015 5:19:14 AM
AVEO Oncology (AVEO) Announces Presentation Of Final Results Of Extension Study 902 And FDA Regulatory Feedback For Advancing Tivozanib In Renal Cell Carcinoma 5/20/2015 12:29:20 PM